

Prevalence of steatosis and fibrosis in young adults in th

The Lancet Gastroenterology and Hepatology  
5, 295-305

DOI: [10.1016/s2468-1253\(19\)30419-4](https://doi.org/10.1016/s2468-1253(19)30419-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Association between behavioural risk factors for chronic liver disease and transient elastography measurements across the UK: a cross-sectional study. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000524.	2.7	3
2	Prevalence of Fatty Liver Disease and Fibrosis Detected by Transient Elastography in Adults in the United States, 2017-2018. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1499-1501.e2.	4.4	38
4	ALT Trends through Childhood and Adolescence Associated with Hepatic Steatosis at 24 Years: A Population-Based UK Cohort Study. <i>Children</i> , 2020, 7, 117.	1.5	4
5	&lt;p&gt;Identifying High-Risk NASH Patients: What We Know so Far&lt;/p&gt;. <i>Hepatic Medicine: Evidence and Research</i> , 2020, Volume 12, 125-138.	2.5	18
6	Fatty liver disease: putting the spotlight on a silent menace for young adults. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 236-238.	8.1	9
7	Prevalence of Liver Steatosis and Fibrosis Detected by Transient Elastography in Adolescents in the 2017&#x2013;2018 National Health and Nutrition Examination Survey. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 384-390.e1.	4.4	60
8	High-Fat Diet&#x2013;Induced Adipose Tissue and Liver Inflammation and Steatosis in Mice Are Reduced by Inhibiting Sialidases. <i>American Journal of Pathology</i> , 2021, 191, 131-143.	3.8	22
9	Predictors of liver fat among children and adolescents from five different ethnic groups. <i>Obesity Science and Practice</i> , 2021, 7, 53-62.	1.9	5
10	Determinants of Physical Activity Engagement in Patients With Nonalcoholic Fatty Liver Disease: The Need for an Individualized Approach to Lifestyle Interventions. <i>Physical Therapy</i> , 2021, 101, .	2.4	7
11	Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in a Golden Syrian Hamster Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
13	Longitudinal associations of total and trunk fat in childhood and adolescence and risk of hepatic steatosis at 24&#x2013;years. <i>Pediatric Obesity</i> , 2021, 16, e12773.	2.8	2
14	Recent Epidemiology of Nonalcoholic Fatty Liver Disease. <i>Gut and Liver</i> , 2021, 15, 206-216.	2.9	54
15	Case-finding strategies in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2021, 3, 100219.	4.9	19
16	Associations between Free Sugar and Sugary Beverage Intake in Early Childhood and Adult NAFLD in a Population-Based UK Cohort. <i>Children</i> , 2021, 8, 290.	1.5	4
18	Vitamin B12 Induces Hepatic Fatty Infiltration through Altered Fatty Acid Metabolism. <i>Cellular Physiology and Biochemistry</i> , 2021, 55, 241-255.	1.6	6
19	Association between Sarcopenic Obesity and Nonalcoholic Fatty Liver Disease and Fibrosis detected by Fibroscan. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 227-232.	0.9	8
21	Clinical impact of sexual dimorphism in non&#x2013;alcoholic fatty liver disease&#x2013;(NAFLD) and non&#x2013;alcoholic steatohepatitis (NASH). <i>Liver International</i> , 2021, 41, 1713-1733.	3.9	58
22	Prevalence and factors associated with NAFLD detected by vibration controlled transient elastography among US adults: Results from NHANES 2017&#x2013;2018. <i>PLoS ONE</i> , 2021, 16, e0252164.	2.5	64

#	ARTICLE	IF	CITATIONS
23	Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens). <i>Journal of Medical Ultrasonics</i> (2001), 2021, 48, 489-495.	1.3	14
24	The ART of medicine: Counselling women with liver disease about assisted reproductive technology. <i>Journal of Hepatology</i> , 2021, 74, 1283-1285.	3.7	1
25	Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1438-e1455.	4.4	49
26	Screening for liver fibrosis in primary care: Focus on subjects above 40 and with metabolic risk factors. <i>United European Gastroenterology Journal</i> , 2021, 9, 889-891.	3.8	1
27	Liver Injury in Liver Transplant Patients With COVID-19: A Histopathologic Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1508-1509.	4.4	2
28	NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040. <i>Hepatology</i> , 2021, 74, 3330-3344.	7.3	44
29	Emerging therapeutic opportunities for integrin inhibitors. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 60-78.	46.4	191
30	EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update. <i>Journal of Hepatology</i> , 2021, 75, 659-689.	3.7	676
31	Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis. <i>European Radiology</i> , 2022, 32, 2070-2077.	4.5	13
32	Association of maternal pre-pregnancy BMI and breastfeeding with NAFLD in young adults: a parental negative control study. <i>Lancet Regional Health - Europe</i> , The, 2021, 10, 100206.	5.6	11
33	Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008–2019. <i>Liver International</i> , 2021, , .	3.9	7
34	Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea. <i>Metabolism: Clinical and Experimental</i> , 2021, 123, 154866.	3.4	19
36	Prevalence of High Liver Stiffness and a Screening Strategy Using the SODA-B Score Among US Adults. <i>Hepatology Communications</i> , 2022, 6, 898-909.	4.3	3
37	Combined Metabolic Activators Decrease Liver Steatosis by Activating Mitochondrial Metabolism in Hamsters Fed with a High-Fat Diet. <i>Biomedicines</i> , 2021, 9, 1440.	3.2	8
38	Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. <i>Molecular Systems Biology</i> , 2021, 17, e10459.	7.2	22
39	Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000780.	2.7	14
40	Supplementation with a Specific Combination of Metabolic Cofactors Ameliorates Non-Alcoholic Fatty Liver Disease, Hepatic Fibrosis, and Insulin Resistance in Mice. <i>Nutrients</i> , 2021, 13, 3532.	4.1	11
42	A CD209 ligand and a sialidase inhibitor differentially modulate adipose tissue and liver macrophage populations and steatosis in mice on the Methionine and Choline-Deficient (MCD) diet. <i>PLoS ONE</i> , 2020, 15, e0244762.	2.5	6

#	ARTICLE	IF	CITATIONS
43	Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 752944.	3.5	13
44	Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 465-472.	4.4	15
45	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	2.5	1
46	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00417.	2.5	13
47	Psoas muscle area and paraspinal muscle fat in children and young adults with or without obesity and fatty liver. <i>PLoS ONE</i> , 2021, 16, e0259948.	2.5	1
48	Intensive Lifestyle Management Improves Steatosis and Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2317-2326.e4.	4.4	14
49	Cigarette smoking and liver diseases. <i>Journal of Hepatology</i> , 2022, 77, 191-205.	3.7	40
50	Multimomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis. <i>Advanced Science</i> , 2022, 9, e2104373.	11.2	23
51	Integrin-Mediated Tumorigenesis and Its Therapeutic Applications. <i>Frontiers in Oncology</i> , 2022, 12, 812480.	2.8	4
52	The association of weight gain with nonalcoholic fatty liver disease and fibrosis detected by FibroScan in the United States. <i>Annals of Gastroenterology</i> , 2022, 35, 194-202.	0.6	1
53	Prevalence of non-alcoholic fatty liver disease (NAFLD) and its association with surrogate markers of insulin resistance in patients with type 1 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2022, 186, 109827.	2.8	8
55	The Prevalence of Liver Steatosis and Fibrosis Assessed by Vibration-Controlled Transient Elastography and Controlled Attenuation Parameter in Apparently Healthy Romanian Medical Students. <i>Diagnostics</i> , 2021, 11, 2341.	2.6	6
56	Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. <i>Hepatology Communications</i> , 2022, 6, 2070-2078.	4.3	12
57	COVID-19, childhood obesity, and NAFLD: colliding pandemics. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 499-501.	8.1	10
58	What's new in non-alcoholic fatty liver disease?. <i>Frontline Gastroenterology</i> , 2022, 13, e102-e108.	1.8	9
59	Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. <i>Hormones</i> , 2022, 21, 349-368.	1.9	12
62	Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	1
63	Liver steatosis and metabolic dysfunction-associated fatty liver disease among HIV-positive and negative adults in urban Zambia. <i>BMJ Open Gastroenterology</i> , 2022, 9, e000945.	2.7	2

#	ARTICLE	IF	CITATIONS
64	The future health and economic burden of obesity-attributable type 2 diabetes and liver disease among the working-age population in Saudi Arabia. <i>PLoS ONE</i> , 2022, 17, e0271108.	2.5	6
65	Noninvasive Algorithms for the Case Finding of "At-Risk" Patients with NAFLD. <i>Seminars in Liver Disease</i> , 2022, 42, 313-326.	3.6	7
66	Prevalence of abnormal liver tests and liver fibrosis among rural adults in low and middle-income country: A cross-sectional study. <i>EClinicalMedicine</i> , 2022, 51, 101553.	7.1	2
67	Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	3
68	The prevalence of alcoholic and nonalcoholic fatty liver disease in adolescents and young adults in the United States: analysis of the NHANES database. <i>BMC Gastroenterology</i> , 2022, 22, .	2.0	10
69	Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. <i>Journal of Hepatology</i> , 2023, 78, 191-206.	3.7	50
70	Prepandemic Prevalence Estimates of Fatty Liver Disease and Fibrosis Defined by Liver Elastography in the United States. <i>Digestive Diseases and Sciences</i> , 0, , .	2.3	2
72	Geographical similarity and differences in the burden and genetic predisposition of NAFLD. <i>Hepatology</i> , 2023, 77, 1404-1427.	7.3	43
76	Sex- and region-specific associations of skeletal muscle mass with metabolic dysfunction-associated fatty liver disease. <i>Frontiers in Endocrinology</i> , 0, 13, .	3.5	2
77	High prevalence of liver fibrosis among general population: a Romanian population-based study. <i>Hepatology Communications</i> , 2023, 7, e0032-e0032.	4.3	4
78	Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis. <i>Journal of Affective Disorders</i> , 2023, 329, 184-191.	4.1	2
79	A Vegetarian Diet Significantly Changes Plasma Kynurenine Concentrations. <i>Biomolecules</i> , 2023, 13, 391.	4.0	2
80	Alterations in circulating lipidomic profile in patients with type 2 diabetes with or without non-alcoholic fatty liver disease. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	3.5	1
81	Role of wnt ligand secretion mediator signaling in cancer development. <i>Journal of Cancer Research and Practice</i> , 2023, 10, 1.	0.2	0
82	Performance of Simple Fibrosis Score in Non-Alcoholic Fatty Liver Disease with and without Type 2 Diabetes. <i>Endocrinology and Metabolism</i> , 0, , .	3.0	1
83	Ketohexokinase-C: The mechanistic link between dietary sugars and protein acetylation during liver steatosis. <i>Journal of Hepatology</i> , 2023, , .	3.7	0
84	Association between antidepressant use and liver fibrosis in patients with type 2 diabetes: a population based study. <i>Diabetology and Metabolic Syndrome</i> , 2023, 15, .	2.7	5
85	High prevalence of metabolic diseases, liver steatosis and fibrosis among Chinese psychiatric patients. <i>BMC Psychiatry</i> , 2023, 23, .	2.6	0

#	ARTICLE	IF	CITATIONS
86	Non-alcoholic fatty liver and fibrosis is associated with cardiovascular structure and function in young adults. <i>Hepatology Communications</i> , 2023, 7, .	4.3	2
87	Fibroscan-aspartate aminotransferase (FAST) score predicts liver-related outcomes, but not extra-hepatic events, in a multicenter cohort of people with HIV. <i>Clinical Infectious Diseases</i> , 0, , .	5.8	0
88	Transient Elastography as the First-Line Assessment of Liver Fibrosis and Its Correlation with Serum Markers. <i>Medicina (Lithuania)</i> , 2023, 59, 752.	2.0	0
89	Increased Risk of Young-Onset Digestive Tract Cancers Among Young Adults Age 20-39 Years With Nonalcoholic Fatty Liver Disease: A Nationwide Cohort Study. <i>Journal of Clinical Oncology</i> , 2023, 41, 3363-3373.	1.6	11
90	Development of a reference and proficiency chemical list for human steatosis endpoints in vitro. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
91	Comorbid Conditions of Pediatric Obesity. , 2023, , 153-198.		0
92	A systematic review and meta-analysis of randomized controlled trials to evaluate plant-based omega-3 polyunsaturated fatty acids in nonalcoholic fatty liver disease patient biomarkers and parameters. <i>Nutrition Reviews</i> , 2024, 82, 143-165.	5.8	1
93	Waist to height ratio in nonalcoholic fatty liver disease – Systematic review and meta-analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2023, 47, 102160.	1.5	1
94	Remnant cholesterol has a non-linear association with non-alcoholic fatty liver disease. <i>Diabetes Research and Clinical Practice</i> , 2023, 201, 110733.	2.8	9
95	Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China. <i>Gastroenterology</i> , 2023, 165, 1025-1040.	1.3	16
96	No effect of multi-strain probiotic supplementation on metabolic and inflammatory markers and newborn body composition in pregnant women with obesity: Results from a randomized, double-blind placebo-controlled study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2023, , .	2.6	0
97	Updates in metabolic dysfunction-associated fatty liver disease (MAFLD) in children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 0, , .	1.8	2
98	Association between liver fibrosis and stroke recurrence in young patients with ischemic stroke. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2024, 34, 112-120.	2.6	0
99	Effect of functional resistance training on the structure and function of the heart and liver in patients with non-alcoholic fatty liver. <i>Scientific Reports</i> , 2023, 13, .	3.3	1
100	Vibration Controlled Transient Elastography in Screening for Silent Liver Diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2023, 35, 1204-1210.	1.6	0
101	Non-alcoholic fatty liver disease, cardiovascular system and kidney function in young adults. <i>Åno-Rossijskij Åurnal TerapevtiÅeskoj Praktiki</i> , 2023, 4, 15-21.	0.3	0
102	Prevalence and Determinants of Undiagnosed Liver Steatosis and Fibrosis in a Nationally Representative Sample of US Adults. <i>Cureus</i> , 2023, , .	0.5	0
103	The impact of projected increases in obesity prevalence on incident liver disease in the UK: Insights from Bayesian-network modelling. , 2023, , .		0

#	ARTICLE	IF	CITATIONS
104	Changes in Fatty Liver Disease and Incident Diabetes Mellitus in Young Korean Adults. <i>American Journal of Preventive Medicine</i> , 2023, , .	3.0	0
105	Liver fibrosis and outcomes of atrial fibrillation: the FIB-4 index. <i>Clinical Research in Cardiology</i> , 2024, 113, 313-323.	3.3	0
106	Analysis of the mediating role of BMI in associations of different folate forms with hepatic steatosis and liver fibrosis in adolescents in the USA: results from the NHANES 2017-2018. <i>Frontiers in Endocrinology</i> , 0, 14, .	3.5	1
107	Non-alcoholic fatty liver disease increases the risk of cardiovascular disease in young adults and children: a systematic review and meta-analysis of cohort studies. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	2.4	1
108	The Use of Noninvasive Velacur <sup>®</sup> for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study. <i>International Journal of Hepatology</i> , 2024, 2024, 1-9.	1.1	0
109	Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes. <i>Diabetes Care</i> , 2024, 47, 668-675.	8.6	0
110	Red meat intake, faecal microbiome, serum trimethylamine N-oxide and hepatic steatosis among Chinese adults. <i>Liver International</i> , 2024, 44, 1142-1153.	3.9	0
111	ITGAV Promotes the Progression of Head and Neck Squamous Cell Carcinoma. <i>Current Oncology</i> , 2024, 31, 1311-1322.	2.2	0
112	The Metabolic Impact of Nonalcoholic Fatty Liver Disease on Cognitive Dysfunction: A Comprehensive Clinical and Pathophysiological Review. <i>International Journal of Molecular Sciences</i> , 2024, 25, 3337.	4.1	0
113	Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2024, 36, 802-810.	1.6	0
114	Prevalence, trends, and characteristics of metabolic dysfunction-associated steatotic liver disease among the US population aged 12-79 years. <i>European Journal of Gastroenterology and Hepatology</i> , 2024, 36, 636-645.	1.6	0